skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Of the big blue chip pharma companies, which are your favourite that you would buy now? Please include others if you prefer others.
Read Answer Asked by Douglas on November 02, 2021
Q: I have a 2/3 position in MDT whose share price has fallen much more than I expected due to a product recall. Was the said recall bad enough to warrant such a drop? I am tempted to top up my position. I hesitate, thinking there must be some bad news out there that I am unaware of. Is there?

MDT seems to have high trailing P/E probably due to elective surgery being postponed. Do you have the following: PEG; fwd P/E; ROE; ROCI ?

I also wonder if my views towards MDT are biased because I see it on the AAII dividend model portfolio; on a BAC top picks (issued a couple of weeks ago); and because it seems to have been a reasonably good dividend grower.

Read Answer Asked by Adam on November 02, 2021
Q: Can you provide comments on the Company's annual report?
Also the Company's CEO has repeatedly stated (multiple press releases reference this) that the Company will be at a revenue run rate of $2 million per month by the end of the year. If the Company were to achieve this, what is implied share price based on what competitors are trading at? Based on my estimates of $24m of annual revenue and comparables trading at 25x revenue this would imply a share price potential of over $3. It is currently just over $1.
Read Answer Asked by Shyam on November 01, 2021
Q: Spectral Medical (T.EDT) has multiple FDA approvals in it's stable including a wholly-owned Dialco division with a state-of-the-art home dialysis unit. Their core business is currently involved in a phase 4 confirmatory trial for sepsis in the US where their PMX filter is being used in a 2:1 ratio vs. the placebo or standard of care with a critical 28 day mortality endpoint. Data from the phase 3 trial being used too ( initially advertised as FAILED). Are you ready to be constructive on this? 30 cents? really?? Something seems a little off here.
Read Answer Asked by Paul on October 28, 2021
Q: Could you weigh in on your views of TDOCs Earnings today? They continue to have increasing net losses from stock compensation and amortization expense. But I would think those are temporary. Top line growth is solid and it's an industry leader in the space.

The share price valuation seems unreasonable. It continues to stay barely above pre-covid levels after making a huge acquisition and going through a pandemic with companies looking to add telehealth capabilities to their benefit plans.

What am I missing?

Thanks as always!
Read Answer Asked by TRINA on October 28, 2021
Q: I currently hold Abbvie and looking to add a second health care sector name to our portfolio. This is a dividend focused portfolio and I'm considering AMGN right now given its 3.8% yield and 5 year dividend growth rate of over 10%. Any thoughts on AMGN and/or another preferred health care holding to add to our Abbvie holding?
Read Answer Asked by Serei on October 25, 2021
Q: When comparing the two companies would you say there’s a lot of overlap in their businesses? Is one diversified enough in healthcare owning both and if not, which would you prefer? Also, could you recommend a few HC stocks that would compliment either? Thanks!
Read Answer Asked by Michael on October 25, 2021
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!